Talis BiomedicalTLIS
13F holders, Q3 2024 (September 30)2holders −16
0new positions
16sold out
$1.85avg. 13F price*
At the end of Q3 2024, 2 institutions reported holding Talis Biomedical Corp. (TLIS) in their 13F filings, down 16 from Q2 2024. 0 opened new positions and 16 sold out. The largest holders were BML Capital Management, LLC ($460K) and Steward Partners Investment Advisory, LLC ($272).
- Company
- Talis Biomedical Corp.
- CUSIP
- 87424L207
- Latest filing quarter
- Q4 2024
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 16 | $6.4M |
All 13F filers, Q2 2024 → Q3 2024: 205,959 shares bought and 742,333 shares sold, net −536,374 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| BML Capital Management, LLC | 0.27% | Add +481.9% | 248,702 | $460K |
| Steward Partners Investment Advisory, LLC | 0.00% | No change | 147 | $272 |
"% of holder's portfolio" is TLIS's weight in each manager's 13F, not the share of Talis Biomedical Corp. the manager owns.